Abstract
Patients with classic congenital adrenal hyperplasia (CAH) often require supraphysiologic doses of glucocorticoids to replace missing cortisol and reduce adrenal androgens. Current treatments aim to control androgen-driven symptoms/impacts but can result in glucocorticoid-related side effects/complications. This study aimed to understand the preferences of adults with classic CAH for the benefits of a potential new adjunctive therapy that could provide better androgen control with lower glucocorticoid doses via an online discrete choice experiment (DCE).
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
